Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010

Diagnostic Microbiology and Infectious Disease
Anne Marie QueenanTodd A Davies

Abstract

Multidrug resistance among Acinetobacter spp. leaves few effective antibiotic options for treatment. To monitor antibiotic resistance in Acinetobacter spp., the US CAPITAL 2010 Surveillance data were evaluated by patient demographics, specimen source, and hospital ward. Isolates (N=514) were collected from 65 sites across the USA and Puerto Rico. Isolates were centrally tested for susceptibility to carbapenems and key antimicrobials by broth microdilution. Colistin was the most effective agent tested, with 95% susceptibility. The overall susceptibility of Acinetobacter spp. was low (39% for piperacillin/tazobactam, 41% for levofloxacin, 45% for ceftazidime, 47-51% for the carbapenems, and 58% for tobramycin). Multidrug resistance (MDR), defined as resistance to ≥3 antimicrobial agent groups, was detected in 54% of the isolates. MDR isolates were most common among elderly patients (65%), lower respiratory tract isolates (62%), and inpatient/intensive care unit isolates (54-58%). These data update trends in the distribution and prevalence of the MDR phenotype in Acinetobacter spp.

References

Mar 21, 2007·Emerging Infectious Diseases·Rebecca H SunenshineArjun Srinivasan
Dec 12, 2007·Antimicrobial Agents and Chemotherapy·Christian G GiskeUNKNOWN ReAct-Action on Antibiotic Resistance
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lisa L Maragakis, Trish M Perl
Oct 25, 2008·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Alicia I HidronUNKNOWN Participating National Healthcare Safety Network Facilities
Aug 25, 2009·The Journal of Hospital Infection·K J Towner
Dec 10, 2009·The Journal of Antimicrobial Chemotherapy·Paul G HigginsHarald Seifert
Jan 6, 2010·International Journal of Antimicrobial Agents·Nicola C Gordon, David W Wareham
May 14, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D M SengstockK S Kaye
Sep 22, 2010·Antimicrobial Agents and Chemotherapy·Jennifer H MoffattJohn D Boyce
Jan 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yu-Chung ChuangShan-Chwen Chang
Sep 16, 2011·Journal of Clinical Microbiology·Jennifer M Adams-HaduchYohei Doi
Nov 25, 2011·International Journal of Antimicrobial Agents·Marie Kempf, Jean-Marc Rolain

❮ Previous
Next ❯

Citations

Feb 21, 2013·Antimicrobial Agents and Chemotherapy·Jessica A O'HaraYohei Doi
Jul 23, 2013·American Journal of Infection Control·Yuriko FukutaYohei Doi
Oct 13, 2015·Antimicrobial Resistance and Infection Control·Darcy EllisElaine Larson
Dec 17, 2014·Expert Opinion on Pharmacotherapy·Abrar K ThabitDavid P Nicolau
Sep 11, 2012·Diagnostic Microbiology and Infectious Disease·Phillip J BergenJian Li
Jan 30, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Zubair A QureshiYohei Doi
May 22, 2016·Infectious Disease Clinics of North America·David van Duin, David L Paterson
Mar 31, 2017·Infectious Diseases and Therapy·Jennifer N LashinskyKeith S Kaye
Feb 26, 2015·Antimicrobial Agents and Chemotherapy·Dana R BowersVincent H Tam
May 28, 2015·Journal of Bacteriology·Kyle A TiptonPhilip N Rather
Oct 10, 2014·Infection & chemotherapy·Chang-Seop Lee, Yohei Doi
Mar 1, 2019·Acta Microbiologica Et Immunologica Hungarica·Júlia RadóSándor Szoboszlay
Apr 25, 2019·Antibiotics·Justin R LenhardKeith S Kaye
Mar 6, 2017·Infectious Diseases and Therapy·Eric WenzlerEllie J C Goldstein
Aug 24, 2016·Current Opinion in Critical Care·Nina M ClarkJoseph P Lynch
Aug 21, 2018·The Journal of Antimicrobial Chemotherapy·Mustapha M MustaphaYohei Doi
Jan 31, 2021·Pathogens·Francesca Paola NoceraLuisa De Martino
Feb 26, 2021·Pharmacological Reviews·Sue C NangJian Li
Jun 15, 2021·Antimicrobial Agents and Chemotherapy·Jacinda C Abdul-MutakabbirMichael J Rybak
Oct 15, 2021·Infectious Diseases and Therapy·Jacinda C Abdul-MutakabbirZahra Kassamali Escobar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.